Cancer-free after 12 years: Why you’re hearing the C-word more often
Two ASX-listed ventures are among the companies now investing billions of dollars to develop an...
Two ASX-listed ventures are among the companies now investing billions of dollars to develop an...
The burgeoning CAR T therapy industry has passed another significant milestone after the US Food...
Australian listed biotech company Prescient Therapeutics (ASX: PTX) is forging a path for other prospective...
StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each...
Several major pharmaceutical companies have cautioned they’re unable to widely use revolutionary CAR-T cancer treatments,...
There are several ASX stocks fighting cancer but only a few are addressing blood cancers....
Are you looking to add some exposure to the small side of the market to...
Prescient Therapeutics (PTX) outperformed its health sector peers on the ASX today after releasing its...
Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer...
Prescient Therapeutics (PTX) has announced three internal development programs for its immune receptor technology platform,...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.